Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.
Yildirim ME, Karadurmuş N, Ökten İN, Türk HM, Urakçı Z, Arslan Ç, Çelik S, Dane F, Şendur MAN, Bilir C, Karabulut B, Cicin İ, Çubukçu E, Karaca M, Ozcelik M, Artaç M, Tanrikulu E, Alacacioglu A, Açıkgöz Ö, Öven B, Geredeli Ç, Çil T, Harputluoğlu H, Kefeli U, Bozkurt O, Tural D, Sakin A, Yalçın Ş, Gumus M. Yildirim ME, et al. Among authors: artac m. J Oncol Pharm Pract. 2024 Apr 13:10781552241241004. doi: 10.1177/10781552241241004. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38613329
Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.
Benekli M, Gumus M, Ozkan M, Dane F, Elkiran ET, Cicin I, Sevinc A, Aliustaoglu M, Isikdogan A, Meydan N, Oksuzoglu B, Ozyilkan O, Artac M, Ozdemir F, Kilickap S. Benekli M, et al. Among authors: artac m. J Oncol Pharm Pract. 2021 Oct;27(7):1623-1630. doi: 10.1177/1078155220963535. Epub 2020 Oct 13. J Oncol Pharm Pract. 2021. PMID: 33050804
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Tural D, et al. Among authors: artac m. Int J Clin Oncol. 2021 Aug;26(8):1506-1513. doi: 10.1007/s10147-021-01936-6. Epub 2021 May 23. Int J Clin Oncol. 2021. PMID: 34023933
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Erol C, Sendur Mehmet AN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, Hizal M, Arslan C, Sevinc A, Kucukarda A, Erdem D, Kahraman S, Cakir E, Demirkiran A, On S, Dogan I, Erdogan AP, Koca S, Kubilay P, Eren OO, Cilbir E, Celik E, Araz M, Ozyukseler DT, Yildirim ME, Bahceci A, Taskaynatan H, Oyman A, Deniz GI, Menekse S, Kut E, Gulmez A, Sakin A, Nayir E, Acar R, Sen E, Inal A, Turhal S, Kaya AO, Paydas S, Tastekin D, Hacibekiroglu I, Cincin I, Bilici A, Mandel NM, Dede DS, Akinci MB, Oksuzoglu B, Uncu D, Yalcin B, Artac M. Erol C, et al. Among authors: artac m. J Cancer Res Ther. 2022 Dec;18(12 Suppl 2):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21. J Cancer Res Ther. 2022. PMID: 36510987 Free article. Clinical Trial.
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: artac m. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S. Tural D, et al. Among authors: artac m. Eur Urol Focus. 2021 Sep;7(5):1061-1066. doi: 10.1016/j.euf.2020.09.010. Epub 2020 Sep 30. Eur Urol Focus. 2021. PMID: 33008789
118 results